For personalized cancer vaccines, the speed of development from biopsy to injection is critical. Traditional methods are too slow. mRNA technology enables custom vaccine creation in just weeks, making a rapid, tailored response to a patient's specific tumor possible for the first time.

Previous cancer vaccine attempts using "shared antigens" failed. Moderna's success stems from creating a unique mRNA vaccine for each patient after discovering that roughly 90% of the targeted cancer antigens differ between individuals. This finding proves that a highly personalized approach is not just an edge case, but a core requirement for the therapy's efficacy.

The next breakthrough in RNA therapeutics won't come from a single innovation. It requires combining two key elements: a 'programmable' mRNA payload designed to be active only in specific cells, and a targeted delivery system to get it there. This two-part solution represents the next generation of in-vivo therapies.

The Keynote 942 study didn't just show clinical improvement; it demonstrated that the neoantigen vaccine expanded specific T-cell clones associated with positive patient response. This confirms the therapy's intended biological mechanism of action, a critical step for validating this new class of cancer treatment.

Even though companies like Moderna (mRNA) and Transgene (viral vector) use different platforms, positive results from any of them help validate the entire individualized neoantigen approach for investors and clinicians. The massive unmet medical need ensures the market is large enough to support multiple successful players.

While personalized cancer vaccines require extracting and processing a patient's tumor, Create Medicines' in vivo approach is entirely off-the-shelf. By delivering the programming directly into the body, they enable the patient's own immune system to do the complex, personalized work of attacking the cancer itself.

Unlike chemotherapy, neoadjuvant immunotherapy appears more effective than adjuvant therapy because it leverages the in-situ tumor and its associated lymph nodes as a 'training ground.' This allows the immune system to generate a robust, specific anti-tumor response before the primary tumor and nodal basin are surgically removed.

Moderna's strategy isn't limited to melanoma. The first prong is augmenting existing checkpoint inhibitors (like Keytruda) where they work. The second is acting as a monotherapy in early-stage disease where checkpoints are too risky. The third is entering markets where inhibitors have failed entirely, such as pancreas cancer, due to its orthogonal mechanism of action.

Unlike permanent gene-editing, the company's mRNA-based CAR-T therapy is transient, with T-cell programming lasting only 7-10 days. This temporary effect enhances safety by avoiding permanent genetic changes and provides crucial flexibility to repeat or adjust dosing to achieve desired durability, much like a traditional drug.